Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics

Assembly Biosciences, Inc. (ASMB): $3.47

0.00 (0.00%)

POWR Rating

Component Grades














  • Value is the dimension where ASMB ranks best; there it ranks ahead of 76.09% of US stocks.
  • ASMB's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
  • ASMB ranks lowest in Quality; there it ranks in the 8th percentile.

ASMB Stock Summary

  • As for revenue growth, note that ASMB's revenue has grown 364.31% over the past 12 months; that beats the revenue growth of 97.91% of US companies in our set.
  • In terms of volatility of its share price, ASMB is more volatile than 94.85% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ASMB comes in at -29.28% -- higher than that of just 9.61% of stocks in our set.
  • Stocks that are quantitatively similar to ASMB, based on their financial statements, market capitalization, and price volatility, are RCUS, ANAB, DCPH, ZGNX, and CASI.
  • ASMB's SEC filings can be seen here. And to visit Assembly Biosciences Inc's official web site, go to

ASMB Valuation Summary

  • ASMB's price/sales ratio is 1.9; this is 47.22% lower than that of the median Healthcare stock.
  • ASMB's price/earnings ratio has moved up 0.9 over the prior 129 months.
  • ASMB's price/sales ratio has moved NA NA over the prior 129 months.

Below are key valuation metrics over time for ASMB.

Stock Date P/S P/B P/E EV/EBIT
ASMB 2020-08-14 13.1 2.6 -9.6 -8.4
ASMB 2018-06-15 81.1 9.4 -21.4 -16.6
ASMB 2017-09-12 162.5 8.7 -9.8 -8.9
ASMB 2017-09-06 157.5 8.5 -9.5 -8.6
ASMB 2013-09-23 NA 1.7 -3.0 -1.1
ASMB 2013-01-02 NA 1.5 -0.8 -0.2

ASMB Price Target

For more insight on analysts targets of ASMB, see our ASMB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.95 Average Broker Recommendation 1.5 (Moderate Buy)

ASMB Stock Price Chart Interactive Chart >

Price chart for ASMB

ASMB Price/Volume Stats

Current price $3.47 52-week high $23.39
Prev. close $3.47 52-week low $3.32
Day low $3.36 Volume 814,400
Day high $3.48 Avg. volume 1,188,408
50-day MA $3.83 Dividend yield N/A
200-day MA $5.76 Market Cap 139.35M

Assembly Biosciences, Inc. (ASMB) Company Bio

Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.

ASMB Latest News Stream

Event/Time News Detail
Loading, please wait...

ASMB Latest Social Stream

Loading social stream, please wait...

View Full ASMB Social Stream

Latest ASMB News From Around the Web

Below are the latest news stories about Assembly Biosciences Inc that investors may wish to consider to help them evaluate ASMB as an investment opportunity.

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 28, 2021

Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug development experienceSOUTH SAN FRANCISCO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that Sir Michael Houghton, PhD, has been appointed to the company’s board of directors. Dr. Houghton was awarded the 2020 Nobel P

Yahoo | July 20, 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to three new employees to purchase an aggregate of 21,520 shares of the Companys common stock with an exercise price of $3.82 per share, the closing price of Assembly Bios common stock on July 1, 2021. The stock options were granted as material inducements to the new employees to accept the Companys offers of employment.

Intrado Digital Media | July 2, 2021

If You Had Bought Assembly Biosciences' (NASDAQ:ASMB) Shares Three Years Ago You Would Be Down 90%

It's not possible to invest over long periods without making some bad investments. But really bad investments should be...

Yahoo | June 26, 2021

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021

SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced data from its three clinical-stage core inhibitor programs, vebicorvir (VBR or ABI-H0731), ABI-H2158 (2158), and ABI-H3733 (3733), in an oral presentation and two poster presentations during the International Liver Congress™ 2021, the Annual Meeting of the European Ass

Yahoo | June 23, 2021

Read More 'ASMB' Stories Here

ASMB Price Returns

1-mo -5.45%
3-mo -16.59%
6-mo -40.58%
1-year -84.37%
3-year -91.67%
5-year -37.25%
YTD -42.64%
2020 -70.43%
2019 -9.55%
2018 -50.01%
2017 272.43%
2016 61.78%

Continue Researching ASMB

Want to see what other sources are saying about Assembly Biosciences Inc's financials and stock price? Try the links below:

Assembly Biosciences Inc (ASMB) Stock Price | Nasdaq
Assembly Biosciences Inc (ASMB) Stock Quote, History and News - Yahoo Finance
Assembly Biosciences Inc (ASMB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9953 seconds.